作者
Bradley D Hunter, Megan Herr, Philip J Meacham, Ferdous Barlaskar, Andrew G Evans, W Richard Burack, Jane L Liesveld, Michael W Becker, Laurie A Milner, Louis S Constine, Sughosh Dhakal, Paul M Barr, Jonathan W Friedberg, Carla Casulo
发表日期
2017/3/1
期刊
Clinical Lymphoma Myeloma and Leukemia
卷号
17
期号
3
页码范围
145-151
出版商
Elsevier
简介
Background
The standard of care for diffuse large B-cell lymphoma (DLBCL) relapsing after front-line therapy is high-dose chemotherapy and autologous stem cell transplantation (ASCT). Evidence has suggested that early relapses (ie, within 1 year) after this approach portends exceptionally poor outcomes. However, data examining relapses > 1 year after ASCT for patients with refractory or relapsed DLBCL are limited, in particular, in the rituximab era. We sought to examine the effect of early (≤ 1 year) and late (> 1 year) relapse after ASCT in a single-institution cohort of patients with relapsed and refractory DLBCL treated with chemoimmunotherapy.
Materials and Methods
A retrospective analysis was performed on the data from 85 consecutive patients who had undergone ASCT for biopsy-confirmed relapsed or refractory DLBCL from 2001 to 2010 at the University of Rochester Medical Center. All patients had …
学术搜索中的文章
BD Hunter, M Herr, PJ Meacham, F Barlaskar… - Clinical Lymphoma Myeloma and Leukemia, 2017